Stockscreener 앱 받기
52.38
2.24%
-1.20
시장 영업 전:
52.70
0.32
+0.61%
Crispr Therapeutics Ag 주식(CRSP)의 최신 뉴스
Is This Millionaire-Maker Biotech Stock a Buy Right Now? - The Motley Fool
Why the market dipped but CRISPR Therapeutics AG (CRSP) gained today - MSN
CRISPR Therapeutics AG (CRSP) reports Q1 loss, lags revenue estimates - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 6.1%What's Next? - MarketBeat
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates - TradingView
CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83 - TipRanks
CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated - TipRanks
CRISPR Therapeutics AG Q1 2026 Financial Results, Company Overview, and Key Developments - Minichart
BofA cuts CRISPR Therapeutics stock price target to $83 on valuation - Investing.com Australia
CRISPR Therapeutics Reports Q1 2026 Financial Results, Highlights CASGEVY Growth and Pipeline Progress - Minichart
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
CRISPR's Next Act: Pipeline Expands as CASGEVY Revenue Grows - BriefGlance
CRISPR Therapeutics AG reports results for the quarter ended March 31Earnings Summary - TradingView
CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary - TradingView
CRISPR Therapeutics (NASDAQ: CRSP) posts Q1 2026 loss and sells $600M converts - Stock Titan
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q1 Revenue $1.5M, vs. FactSet Est of $6.1M - marketscreener.com
CASGEVY revenue and cash build at CRISPR Therapeutics (NASDAQ: CRSP) in Q1 2026 - Stock Titan
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Approval And CAR T Pipeline Progress - Sahm
CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Monday - MarketBeat
Pictet Asset Management Holding SA Sells 25,129 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Is Early Casgevy Momentum Reframing CRISPR Therapeutics' (CRSP) Long-Term Profitability Narrative? - Sahm
UBS Group AG Boosts Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Trading the Move, Not the Narrative: (CRSP) Edition - Stock Traders Daily
CRSP Stock Price, Quote & Chart | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
ARK, Catherine Wood disclose 11.79% stake in CRSP (CRSP) - Stock Titan
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know - MSN
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance Singapore
CRSP Price Today: CRISPR Therapeutics AG Stock Price, Quote & Chart | MEXC - MEXC Exchange
Why the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained Today - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
CRISPR Therapeutics Hits Day Low of $48.77 Amid Price Pressure - Markets Mojo
CRISPR Therapeutics shares drop after announcing convertible notes sale - MSN
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note - MSN
CRSP Stock Firms Up As ARK Support And Needham Event Draw Traders - StocksToTrade
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 7.5%Here's Why - MarketBeat
Why Crispr Therapeutics Stock Is Surging Again - TipRanks
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards? - TradingView
3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat
CRISPR Therapeutics AG (CRSP) stock slides as market rises: Facts to know before you trade - MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know - MSN
Why CRISPR Therapeutics AG (CRSP) outpaced the stock market today - MSN
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Volatility - simplywall.st
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - MSN
CRISPR Therapeutics (CRSP) Stock Drops 11% – Bad Earnings, a Free Rival Therapy, and a CEO Selling - MEXC Exchange
0.14%
0.48%
자본화:
|
볼륨(24시간):